Skip to content
OpenCapital
Get started

SAB Biotherapeutics SABS Q4 2025 Annual earnings

Reported March 9, 2026 · After market close

EPS-$0.46Miss by $0.30
Revenue estimate$100.0K
EPS estimate-$0.16

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$125.0K
EPS estimate-$0.29

Versus estimates

Revenue

Q4 2024$100.0KMiss by $20.0K

Diluted EPS

Q1 2026-$0.35Miss by $0.15
Q4 2025-$0.46Miss by $0.30
Q3 2025-$0.21Beat by $0.38Q2 2025-$1.09Miss by $0.27Q1 2025-$0.56Beat by $0.44Q4 2024-$1.23Miss by $0.07

Ask the moment SAB Biotherapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did SAB Biotherapeutics report Q4 2025 earnings?
SAB Biotherapeutics (SABS) reported Q4 2025 earnings on March 9, 2026 after market close.
What were SAB Biotherapeutics's Q4 2025 revenue and EPS?
SAB Biotherapeutics reported eps of $-0.46 for Q4 2025.
Did SAB Biotherapeutics beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.16 by $0.30.
How did SAB Biotherapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 62.6% from $-1.23.
Where can I find SAB Biotherapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-099376) and the 10-K periodic report (0001833214-26-000003) directly on SEC EDGAR. The filing index links above go to sec.gov.